COVID-19 is not "just another flu": a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria.
Austria
COVID-19
Comparison
In-hospital
Influenza
Mortality
SARS-CoV-2
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
09
12
2020
accepted:
26
03
2021
pubmed:
14
5
2021
medline:
26
11
2021
entrez:
13
5
2021
Statut:
ppublish
Résumé
COVID-19 is regularly compared to influenza. Mortality and case-fatality rates vary widely depending on incidence of COVID-19 and the testing policy in affected countries. To date, data comparing hospitalized patients with COVID-19 and influenza is scarce. Data from patients with COVID-19 were compared to patients infected with influenza A (InfA) and B (InfB) virus during the 2017/18 and 2018/19 seasons. All patients were ≥ 18 years old, had PCR-confirmed infection and needed hospital treatment. Demographic data, medical history, length-of-stay (LOS), complications including in-hospital mortality were analyzed. In total, 142 patients with COVID-19 were compared to 266 patients with InfA and 300 with InfB. Differences in median age (COVID-19 70.5 years vs InfA 70 years and InfB 77 years, p < 0.001) and laboratory results were observed. COVID-19 patients had fewer comorbidities, but complications (respiratory insufficiency, pneumonia, acute kidney injury, acute heart failure and death) occurred more frequently. Median length-of-stay (LOS) was longer in COVID-19 patients (12 days vs InfA 7 days vs. InfB 7 days, p < 0.001). There was a fourfold higher in-hospital mortality in COVID-19 patients (23.2%) when compared with InfA (5.6%) or InfB (4.7%; p < 0.001). In hospitalized patients, COVID-19 is associated with longer LOS, a higher number of complications and higher in-hospital mortality compared to influenza, even in a population with fewer co-morbidities. This data, a high reproduction number and limited treatment options, alongside excess mortality during the SARS-CoV-2 pandemic, support the containment strategies implemented by most authorities.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 is regularly compared to influenza. Mortality and case-fatality rates vary widely depending on incidence of COVID-19 and the testing policy in affected countries. To date, data comparing hospitalized patients with COVID-19 and influenza is scarce.
METHODS
METHODS
Data from patients with COVID-19 were compared to patients infected with influenza A (InfA) and B (InfB) virus during the 2017/18 and 2018/19 seasons. All patients were ≥ 18 years old, had PCR-confirmed infection and needed hospital treatment. Demographic data, medical history, length-of-stay (LOS), complications including in-hospital mortality were analyzed.
RESULTS
RESULTS
In total, 142 patients with COVID-19 were compared to 266 patients with InfA and 300 with InfB. Differences in median age (COVID-19 70.5 years vs InfA 70 years and InfB 77 years, p < 0.001) and laboratory results were observed. COVID-19 patients had fewer comorbidities, but complications (respiratory insufficiency, pneumonia, acute kidney injury, acute heart failure and death) occurred more frequently. Median length-of-stay (LOS) was longer in COVID-19 patients (12 days vs InfA 7 days vs. InfB 7 days, p < 0.001). There was a fourfold higher in-hospital mortality in COVID-19 patients (23.2%) when compared with InfA (5.6%) or InfB (4.7%; p < 0.001).
CONCLUSION
CONCLUSIONS
In hospitalized patients, COVID-19 is associated with longer LOS, a higher number of complications and higher in-hospital mortality compared to influenza, even in a population with fewer co-morbidities. This data, a high reproduction number and limited treatment options, alongside excess mortality during the SARS-CoV-2 pandemic, support the containment strategies implemented by most authorities.
Identifiants
pubmed: 33983624
doi: 10.1007/s15010-021-01610-z
pii: 10.1007/s15010-021-01610-z
pmc: PMC8117126
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
907-916Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
COVID-19 Dashboard. Available at: https://coronavirus.jhu.edu/map.html . Accessed 9 December 2020
Fernandes N. Economic effects of coronavirus outbreak (COVID-19) on the world economy. Available at https://ssrn.com/abstract=3557504 . Accessed 20 July 2020
Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020;25:2000058. https://doi.org/10.2807/1560-7917.ES.2020.25.4.2000058 (Published correction appears in Euro Surveill. 2020 Feb; 25(7)).
doi: 10.2807/1560-7917.ES.2020.25.4.2000058
pmcid: 7001239
Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26:1470–7. https://doi.org/10.3201/eid2607.200282 .
doi: 10.3201/eid2607.200282
pubmed: 32255761
pmcid: 7323562
Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis. 2014;14:480. https://doi.org/10.1186/1471-2334-14-480 (Published 2014 Sep 4).
doi: 10.1186/1471-2334-14-480
pubmed: 25186370
pmcid: 4169819
Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285–300. https://doi.org/10.1016/S0140-6736(17)33293-2 (Published correction appears in Lancet. 2018 Jan 19).
doi: 10.1016/S0140-6736(17)33293-2
pubmed: 29248255
Zucs P, Buchholz U, Haas W, Uphoff H. Influenza associated excess mortality in Germany, 1985–2001. Emerg Themes Epidemiol. 2005;2:6. https://doi.org/10.1186/1742-7622-2-6 .
doi: 10.1186/1742-7622-2-6
pubmed: 15969758
pmcid: 1188065
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. https://doi.org/10.1001/jama.2020.6019 .
doi: 10.1001/jama.2020.6019
pubmed: 33165621
pmcid: 7492917
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382:1787–99. https://doi.org/10.1056/NEJMoa2001282 .
doi: 10.1056/NEJMoa2001282
pubmed: 32187464
Horby P, Lim WS, Emberson J, et al. Dexamethasone in hospitalized patients with COVID-19–preliminary report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436 (published online ahead of print, 2020 Jul 17).
doi: 10.1056/NEJMoa2021436
pubmed: 33031652
pmcid: 7490833
Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25:2000180. https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000180 .
doi: 10.2807/1560-7917.ES.2020.25.10.2000180
pmcid: 7078829
Day M. COVID-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. BMJ. 2020;368:m1165. https://doi.org/10.1136/bmj.m1165 (Published 2020 Mar 23).
doi: 10.1136/bmj.m1165
pubmed: 32205334
Leung NH, Xu C, Ip DK, Cowling BJ. Review article: the fraction of influenza virus infections that are asymptomatic: a systematic review and meta-analysis. Epidemiology. 2015;26:862–72. https://doi.org/10.1097/EDE.0000000000000340 .
doi: 10.1097/EDE.0000000000000340
pubmed: 26133025
pmcid: 4586318
Wilson N, Kvalsvig A, Barnard LT, Baker MG. Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emerg Infect Dis. 2020;26:1339–441. https://doi.org/10.3201/eid2606.200320 .
doi: 10.3201/eid2606.200320
pubmed: 32168463
pmcid: 7258483
Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;20:773. https://doi.org/10.1016/S1473-3099(20)30195-X .
doi: 10.1016/S1473-3099(20)30195-X
pubmed: 32171390
pmcid: 7118515
Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20:630–1. https://doi.org/10.1016/S1473-3099(20)30257-7 (Published correction appears in Lancet Infect Dis. 2020 Apr 6).
doi: 10.1016/S1473-3099(20)30257-7
pubmed: 32240633
pmcid: 7156221
Karolyi M, Pawelka E, Daller S, et al. Is there a clinical difference between influenza A and B virus infections in hospitalized patients?: Results after routine polymerase chain reaction point-of-care testing in the emergency room from 2017/2018. Wien Klin Wochenschr. 2019;131:362–8. https://doi.org/10.1007/s00508-019-1519-0 .
doi: 10.1007/s00508-019-1519-0
pubmed: 31214922
pmcid: 7101895
Chen S, Feng H, Huang S, et al. Time windows for predicting deterioration in COVID-19 patients (4/10/2020). Available at SSRN: https://ssrn.com/abstract=3576808 . http://dx.doi.org/ https://doi.org/10.2139/ssrn.3576808
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. https://doi.org/10.1056/NEJMoa2002032 .
doi: 10.1056/NEJMoa2002032
pubmed: 32109013
pmcid: 32109013
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3 (Published correction appears in Lancet. 2020 Mar 28; 395(10229):1038).
doi: 10.1016/S0140-6736(20)30566-3
pubmed: 32171076
pmcid: 32171076
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020;382:e102. https://doi.org/10.1056/NEJMoa2007621 (Retracted in: N Engl J Med. 2020 Jun 4).
doi: 10.1056/NEJMoa2007621
pubmed: 32356626
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648 (Published online ahead of print, 2020 Feb 24).
doi: 10.1001/jama.2020.2648
pubmed: 33170236
pmcid: 7711563
Henry C, Palm AE, Krammer F, Wilson PC. From original antigenic sin to the universal influenza virus vaccine. Trends Immunol. 2018;39:70–9. https://doi.org/10.1016/j.it.2017.08.003 .
doi: 10.1016/j.it.2017.08.003
pubmed: 28867526
Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original antigenic sin: how first exposure shapes lifelong anti-influenza virus immune responses. J Immunol. 2019;202:335–40. https://doi.org/10.4049/jimmunol.1801149 .
doi: 10.4049/jimmunol.1801149
pubmed: 30617114
Pawelka E, Karolyi M, Daller S, et al. Influenza virus infection: an approach to identify predictors for in-hospital and 90-day mortality from patients in Vienna during the season 2017/18. Infection. 2020;48:51–6. https://doi.org/10.1007/s15010-019-01335-0 .
doi: 10.1007/s15010-019-01335-0
pubmed: 31203513
European mortality monitoring. Available at https.// www.euromomo.eu/ . Accessed 20 July 2020.
Chen J, Jiang Q, Xia X, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell. 2020. https://doi.org/10.1111/acel.13168 .
doi: 10.1111/acel.13168
pubmed: 33378138
pmcid: 7811843
Culebras E, Hernández F. ACE2 is on the X chromosome: could this explain COVID-19 gender differences? Eur Heart J. 2020. https://doi.org/10.1093/eurheartj/ehaa521 (published online ahead of print, 2020 Jun 24).
doi: 10.1093/eurheartj/ehaa521
pubmed: 32577716
Ingram PR, Inglis T, Moxon D, Speers D. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med. 2010;36:528–32. https://doi.org/10.1007/s00134-009-1746-3 .
doi: 10.1007/s00134-009-1746-3
pubmed: 20069274
pmcid: 7080172
von Baum H, Schweiger B, Welte T, et al. How deadly is seasonal influenza-associated pneumonia? The german competence network for community-acquired pneumonia. Eur Respir J. 2011;37:1151–7. https://doi.org/10.1183/09031936.00037410 .
doi: 10.1183/09031936.00037410
Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16:e321–31. https://doi.org/10.1016/j.ijid.2012.01.003 .
doi: 10.1016/j.ijid.2012.01.003
pubmed: 22387143